2
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
78
Neoplasms
69
Prostatic Neoplasms
51
Colorectal Neoplasms
45
Lung Neoplasms
39
Carcinoma, Non-Small-Cell Lung
28
Hematologic Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
20
Head and Neck Neoplasms
20
Urinary Bladder Neoplasms
15
Ovarian Neoplasms
15
Multiple Myeloma
15
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Motor Activity
11
Leukemia, Myeloid, Acute
11
Glioblastoma
10
Uterine Cervical Neoplasms
9
Triple Negative Breast Neoplasms
9
Gastrointestinal Neoplasms
9
Colonic Neoplasms
9
Melanoma
8
Hematopoietic and Lymphatic System Neoplasm
8
Glioma
8
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
COVID-19
8
Anxiety Disorders
8
Anatomic Stage I Breast Cancer AJCC v8
8
Interventions
Ipilimumab
29
Nivolumab
23
pembrolizumab
14
incomplete Freund's adjuvant
10
Cyclophosphamide
10
Melphalan
9
Interleukin-2
9
CTLA-4 Antigen
8
tebentafusp
7
sargramostim
7
Temozolomide
7
MART-1 Antigen
7
Dacarbazine
7
Ranibizumab
6
montanide ISA 51
5
fludarabine phosphate
5
fludarabine
5
Sunitinib
5
Radiosurgery
5
Carboplatin
5
Blood Specimen Collection
5
Bevacizumab
5
aldesleukin
4
aflibercept
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
trametinib
3
sotrastaurin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Standard of Care
×
Clear all
NCT05266430
2023-08-09
IL
Aura Biosciences
Terminated
2 enrolled